TotalMarketCap

Halozyme Therapeutics

HALONasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$12.453 B

$109.72 +1.30%

Close of 7 Oct 2026

As of 7 Oct 2026, Halozyme Therapeutics (HALO) has a market capitalization of $12.5B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$1.40B

#1339 by revenue

Earnings

$316.9M

#812 by earnings

Shares outstanding

113,498,000

Latest filing cover page

P/E ratio

39.3

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →
  1. #8Neurocrine BiosciencesNBIX$14.8B
  2. #9ExelixisEXEL$14.5B
  3. #10Halozyme TherapeuticsHALO$12.5B
  4. #11Bio-TechneTECH$11.4B
  5. #12Twist BioscienceTWST$11.1B

What if Halozyme Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.8T

$253,655.87

Per share 2,312× higher

Bitcoin $1.67T

$14,716.10

Per share 134× higher

Nvidia $5.77T

$50,799.87

Per share 463× higher

Or at a round number

$20.0B$50.0B$100.0B$200.0B

Where these numbers come from

Share counts and financials for Halozyme Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 8 Oct 2026. Read the methodology.